Shared Vision

A collaborative resource for eye care education

ANNOUNCEMENT: SCIENTIFIC DATA RELEASED

Consistency in Outcomes – Results from Three Different Retrospective Analyses with over 100 children (ages 8-13, age & ethnicity matched)

Presented at Vision By Design by Dr. Doug P. Benoit

≤0.25D

A majority of patients progressed ≤ 0.25D in years 1 and 2 in all three cohorts. Average annual myopia progression in each cohort was < 0.15 D in years 1 and 2.

≤0.10 mm

Average axial length change was less than 0.10 mm per year at years 1 and 2 (approximately consistent with that expected in emmetropic children).[1,2]





Analysis of three independent retrospective studies – 108 real-world myopes wearing NaturalVue Multifocal evaluated at 12 months and 24 months of wear.

Benoit, D.P. (2023, September 7). Consistency in Outcomes – Results from Three Different Retrospective Analyses. Vision By Design. Schaumberg, IL, United States.

1 OLSM: Jones LA, Mitchell GL, Mutti DO et al. Comparison of ocular component growth curves among refractive error groups in children. Invest Ophthalmol Vis Sci 2005; 46: 2317–2327.

2 SCORM: Wong HB, Machin D, Tan SB et al. Ocular component growth curves among Singaporean children with different refractive error status. Invest Ophthalmol Vis Sci 2010; 51: 1341–1347

For more information about this study or other NaturalVue clinical data, contact Dr. Doug Benoit, Executive Director of Medical Affairs at dbenoit@vtvision.com

Consistency in Outcomes – Results from Three Different Retrospective Analyses with over 100 children

- Similar CARE value (cumulative absolute reduction in axial elongation) versus virtual control subjects during the 2-year follow-up period from both cohorts reporting axial length data.
- Year 2 myopia progression data trended closely with Year 1 values.

SER Change Over Time (year)
CAMP Monotherapy, n=5



SER Change Over Time (year)
Lederman n=14



Combined with the 6-year data previously published in Clinical Ophthalmology in 2022, this new analysis suggests NaturalVue Multifocal effectively manages eye growth and refractive error change among children in diverse settings over at least two years of follow up.

The three independently conducted studies included:

1. NaturalVue Monotherapy Subgroup Analysis from The CAMP study (The Clinical Algorithm for Myopia Progression) conducted by Treehouse Eyes®
2. Myopia Control with Extended Depth of Focus Multifocal Contact Lenses, Carolyn R. Lederman, MD & Edward S. Harkness Eye Institute, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY (Presented as a POSTER at the 2023 American Association for Pediatric Ophthalmology and Strabismus 48th Annual Meeting, 29 March-02 April 2023)
3. Subgroup Analysis from NaturalVue 6-year Retrospective data: Cooper J, O'Connor B, Aller T, et al. Reduction of myopic progression using a multifocal soft contact lens: A retrospective cohort study. Clin Ophthalmol. 2022Jul;16:2145-2155.

*CAMP Study Funding/Support: Funding for this project was provided in part by the Euclid Systems Corporation and Visioneering Technologies, Inc., through unrestricted grants. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or the decision to submit the manuscript for publication.

Analysis of three independent retrospective studies – 108 real-world myopes wearing NaturalVue Multifocal evaluated at 12 months and 24 months of wear.

Benoit, D.P. (2023, September 7). Consistency in Outcomes – Results from Three Different Retrospective Analyses. Vision By Design. Schaumberg, IL, United States.

1 OLSM: Jones LA, Mitchell GL, Mutti DO et al. Comparison of ocular component growth curves among refractive error groups in children. Invest Ophthalmol Vis Sci 2005; 46: 2317–2327.

2 SCORM: Wong HB, Machin D, Tan SB et al. Ocular component growth curves among Singaporean children with different refractive error status. Invest Ophthalmol Vis Sci 2010; 51: 1341–1347

For more information about this study or other NaturalVue clinical data, contact Dr. Doug Benoit, Executive Director of Medical Affairs at dbenoit@vtivision.com